Roman Hájek
Speaker at the 19th International Myeloma Society Annual Meeting
Best podcasts with Roman Hájek
Ranked by the Snipd community
Oct 2, 2022 • 3min
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Roman Hájek, from the University of Ostrava, discusses the benefits of isatuximab-based combinations in treating relapsed multiple myeloma patients refractory to lenalidomide-based therapy. The focus is on the efficacy of isatuximab with carfilzomib and dexamethasone, highlighting the role of immunomodulatory agents in improving outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
